Long-lasting resistance to haloperidol-induced catalepsy in male rats chronically treated with caffeine.
Chronic caffeine consumption has been inversely associated with the risk of developing Parkinson's disease. Here we assessed whether chronic caffeine treatment increases the resistance of male Wistar rats to haloperidol (1mg/kg, s.c.)-induced catalepsy, measured in the bar test at 15 min intervals during 3h. Caffeine (5mg/kg/day) was delivered for 6 months via drinking water. Control rats received only tap water. Treatments began when animals were 3-4 months old. In order to unveil long-lasting catalepsy refractoriness not attributable to the presence of caffeine in the brains of rats, they were evaluated from day 18 to day 27 after caffeine withdrawal, a time that is far in excess for the full excretion of a caffeine dose in this species. The average cataleptic immobility measured in caffeine-treated rats (n=23) was 1148+/-140 s, a value 34+/-8% lower than that recorded in control animals (n=20), whose mean immobility was 1736+/-137 s (P=0.0026, t-test). The percentage of catalepsy reduction measured in caffeine-treated rats evaluated on days 18-20 after caffeine discontinuation (-32+/-13%, n=12, P<0.05) was comparable to the catalepsy decrease recorded in those animals tested on days 21-27 (-36+/-10%, n=11, P<0.02), a finding compatible with the notion that the effect was indeed mediated by enduring changes of brain functioning and not by the physical presence of caffeine or its metabolites. Caffeine-treated rats also had higher catalepsy latency scores compared with control rats (P<0.01, U-test). The present findings show that chronic consumption of caffeine produces perdurable resistance to catalepsy induced by dopamine receptor blockade, possibly through enhancement of dopamine transmission, giving further support to the epidemiological results indicating that prolonged caffeine consumption affords neuroprotection against Parkinson's disease.
Góngora-Alfaro
José L
JL
Departamento de Neurociencias, Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán, Avenida Itzáes 490 x 59, Mérida, Yucatán 97000, Mexico. jlgongoralf@gmail.com
Moo-Puc
Rosa E
RE
Villanueva-Toledo
Jairo R
JR
Alvarez-Cervera
Fernando J
FJ
Bata-García
José L
JL
Heredia-López
Francisco J
FJ
Pineda
Juan C
JC
D000818:Animals; D002110:Caffeine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D002375:Catalepsy / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control*; D000697:Central Nervous System Stimulants / Q000494:pharmacology* / Q000627:therapeutic use; D004198:Disease Susceptibility; D065127:Dopamine D2 Receptor Antagonists; D006220:Haloperidol; D008297:Male; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
D000697:Central Nervous System Stimulants; D065127:Dopamine D2 Receptor Antagonists; D018696:Neuroprotective Agents; D002110:Caffeine; D006220:Haloperidol